Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events

Medical Decision Making

Volumn 36, Issue 8, 2016, Pages 965-972

  Briggs, Andrew H ^a   Parfrey, Patrick S ^b   Khan, Nasreen ^c   Tseng, Spring ^d   Dehmel, Bastian ^d   Kubo, Yumi ^d   Chertow, Glenn M ^e   Belozeroff, Vasily ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c IQVIA   (United States)

^d AMGEN INC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cinacalcet; quality of life; randomized clinical trial

Indexed keywords

CALCIMIMETIC AGENT; CINACALCET;

ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; CALCIMIMETIC AGENTS; CARDIOVASCULAR DISEASES; CINACALCET HYDROCHLORIDE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REGRESSION ANALYSIS; RENAL DIALYSIS; RESEARCH DESIGN;

EID: 84989352303     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X16638312     Document Type: Article

References (17)

1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Available from: http://publications.nice.org/uk/pmg9.
2. Neumann PJ, Weinstein MC., Legislating against use of cost-effectiveness information. N Engl J Med. 2010; 363: 1495-7.
3. Sox HC., Quality of life and guidelines for PSA screening. N Engl J Med. 2012; 367 (7): 669-71.
4. Manca A, Hawkins N, Sculpher MJ., Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005; 14: 487-96.
5. Clarke P, Gray A, Holman R., Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002; 22: 340-9.
6. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007; 2: 898-905.
7. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367: 2482-94.
8. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208.
9. Dolan P., Modeling valuations for EuroQol health states. Med Care. 1997; 35: 1095-108.
10. Etzioni RD, Feuer EJ, Sullivan SD, Lin D, Hu C, Ramsey SD., On the use of survival analysis techniques to estimate medical care costs. J Health Econ. 1999; 18: 365-80.
11. Chertow GM, Lu ZJ, Xu X, et al. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial Int. 2012; 16: 188-97.
12. U.S. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf
13. Altman DG., Comparability of randomised groups. The Statistician. 1985; 34: 125-36.
14. Enderlein G, Pocock SJ., Clinical trials: a practical approach. Biom J. 1985; 27: 634.
15. Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH., Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015; 18 (8): 1079-87.
16. Walters SJ, Brazier JE., Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005; 14 (6): 1523-32.
17. Clarke P, Gray A, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005; 48: 868-77.